High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib

Tumor lysis syndrome (TLS) is a life-threatening complication associated with cancer chemotherapy. We retrospectively evaluated the risk of developing TLS in patients with symptomatic multiple myeloma undergoing chemotherapy. Sixty-four patients (median age=71 years, range=48-87 years, 35 males/29 f...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Anticancer research 2016-12, Vol.36 (12), p.6655-6662
Hauptverfasser:	Oiwa, Kana, Morita, Mihoko, Kishi, Shinji, Okura, Miyuki, Tasaki, Toshiki, Matsuda, Yasufumi, Tai, Katsunori, Hosono, Naoko, Ueda, Takanori, Yamauchi, Takahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Bortezomib - therapeutic use Female Humans Kidney Diseases - drug therapy Kidney Diseases - physiopathology Male Middle Aged Multiple Myeloma - complications Tumor Lysis Syndrome - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!